Thursday, October 22, 2020
Eurofins' US Transplant Diagnostics is proud to announce the successful acquisition of the Hawaii Cellular Therapy and Transplant Laboratory (HCTTL). HCTTL will merge with Eurofins VRL, a market leader in US pre-transplant testing, and expand VRL's substantial US geographic footprint.
The addition of this highly regarded and long-standing pillar of the Hawaiian transplant community will further increase VRL's network of laboratories that are now located in 11 states, serving Organ Procurement Organizations, Tissue Banks, and commercial companies needing testing for donated biological materials.
'The laboratory plays a critical role in providing access to therapy by supporting the solid organ transplant program at The Queen's Medical Center, as well as Legacy of Life Hawaii, the State's organ and tissue donation program,' Professor Randal K. Wada, M.D., University of Hawaii said in a statement.
'We are thrilled that under Eurofins VRL, the laboratory will be able to take full advantage of state of the art technologies and be well-positioned to expand services and capacity in the future,' Dr. Wada added.
The acquisition of HCTTL aligns nicely to the Eurofins Transplant Diagnostics strategy of expanding and strengthening the transplant network and maintaining its leadership position in the pre- and post-transplantation organ testing market.
With the combined transplant diagnostics portfolio of Viracor-Eurofins laboratory and Transplant Genomics innovative testing of subclinical rejection detection testing, Eurofins' US Transplant Diagnostics will advance transplant care and aid organ procurement organizations within the region. Please visit http://www.vrl-eurofins.com/for more information.
With over twenty five years of experience in donor eligibility testing, VRL-Eurofins has eleven high complexity testing laboratories located in Denver, Colorado; Dallas, Texas; Boston, Massachusetts; Atlanta, Georgia; Los Angeles, California; Minnesota, Minneapolis; Philadelphia, Pennsylvania; San Ramon; California, Cincinnati, Ohio, Winston-Salem, North Carolina and Honolulu, Hawaii. VRL-Eurofins' focus is performing Donor Eligibility Screening and Microbiology Testing, using the most appropriate regulated testing technologies for the transplant and medical communities. VRL has brought together a diverse professional team with experience in testing, quality, regulatory, and customer service.
With over 30 years of specialized expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients, Viracor Eurofins is committed to helping medical professionals, transplant teams and reference laboratories get results faster, when it matters most. Viracor is passionate about delivering value to its clients by providing timely, actionable information, never losing sight of the connection between the testing it performs and the patients it ultimately serves. Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit https://www.viracor-eurofins.com/.
About Eurofins - the global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter 'Eurofins' or 'the Group'), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group's objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.
As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
Eurofins Scientific SE published this content on 22 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 October 2020 08:49:07 UTC